CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for COSCIENS Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

COSCIENS Biopharma Inc
C/O Norton Rose Fulbright Canada Llp
222 Bay Street, Suite 3000,
Phone: (780) 421-4555p:780 421-4555 TORONTO, ON  M5H 4E3  Canada Ticker: CSCICSCI
This company ceased filing statements with the SEC on 7/6/2026.
Business Summary
COSCIENS Biopharma Inc. is a Canada-based holding company. The Company is operating through its subsidiaries, including Ceapro Inc. (Ceapro) and Nualtis. Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro's primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries. Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs and commercial product manufacturing.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2844 Perfumes, cosmetics, and other toilet preparations
2833 Medicinal chemicals and botanical products
2899 Chemicals and chemical preparations, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Peter H.Puccetti 6/17/2026 5/30/2025
Chief Financial Officer, Senior Vice President GiulianoLa Fratta 5/30/2025 1/24/2022
Senior Vice President, Chief Technology Officer MichelRegnier
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Ceapro Inc 7824 51 Ave NW EDMONTON AB Canada
Nualtis Corp. 6420 Rue Abrams Saint-Laurent QC Canada

Business Names
Business Name
Aeterna Zentaris GmbH
Aeterna Zentaris, Inc.
AEZ
7 additional Business Names available in full report.

General Information
Number of Employees: 28 (As of 12/31/2025)
Outstanding Shares: 1,061,455 (As of 7/7/2026)
Shareholders: 234
Stock Exchange: TSE
Federal Tax Id: 000000000
Fax Number: (418) 948-9191


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, October 3, 2026